City of Hope Medical Center: Burkitt Lymphoma trials

The registry lists 15 Burkitt Lymphoma studies with City of Hope Medical Center as lead sponsor. 3 are open to participants now and 2 have results posted.

Phase 1 11Phase 2 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic LymphomaNot yet recruitingNCT07758673Phase 1
• Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaRecruitingNCT07133997Phase 1
• Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingNCT06918431Phase 2
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First RemissionActive, not recruitingNCT05707273Phase 1
• Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT05157971Phase 1
• Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological MalignanciesCompletedNCT04681105Phase 1
• Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaActive, not recruitingNCT02153580Phase 1
• Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic LeukemiaActive, not recruitingNCT02146924Phase 1
• Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin LymphomaActive, not recruitingNCT01815749Phase 1
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
• Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
• Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated LymphomaCompletedNCT00641381Phase 1